NNOX Quote, Financials, Valuation and Earnings

Can Fite Biofarma has a net margin of -449.98% compared to Nano X Imaging's net margin of --. Nano X Imaging's return on equity of -26.97% beat Can Fite Biofarma's return on equity of --.

Nano X Imaging has a consensus price target of $15.00, signalling upside risk potential of 78.36%. On the other hand Can Fite Biofarma has an analysts' consensus of $14.00 which suggests that it could grow by 803.23%. Given that Can Fite Biofarma has higher upside potential than Nano X Imaging, analysts believe Can Fite Biofarma is more attractive than Nano X Imaging.

Nano X Imaging has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Can Fite Biofarma has a beta of 1.365, suggesting its more volatile than the S&P 500 by 36.503%.

Nano X Imaging has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Can Fite Biofarma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nano X Imaging pays -- of its earnings as a dividend. Can Fite Biofarma pays out -- of its earnings as a dividend.

Nano X Imaging quarterly revenues are $3M, which are larger than Can Fite Biofarma quarterly revenues of --. Nano X Imaging's net income of -$13.6M is higher than Can Fite Biofarma's net income of --. Notably, Nano X Imaging's price-to-earnings ratio is -- while Can Fite Biofarma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nano X Imaging is 45.73x versus 12.73x for Can Fite Biofarma. Usually stocks with elevated PS ratios are considered overvalued.

Compugen has a net margin of -449.98% compared to Nano X Imaging's net margin of 7.45%. Nano X Imaging's return on equity of -26.97% beat Compugen's return on equity of 2.69%.

Nano X Imaging has a consensus price target of $15.00, signalling upside risk potential of 78.36%. On the other hand Compugen has an analysts' consensus of $4.00 which suggests that it could grow by 77.78%. Given that Nano X Imaging has higher upside potential than Compugen, analysts believe Nano X Imaging is more attractive than Compugen.

Nano X Imaging has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Compugen has a beta of 2.588, suggesting its more volatile than the S&P 500 by 158.755%.

Nano X Imaging has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Compugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nano X Imaging pays -- of its earnings as a dividend. Compugen pays out -- of its earnings as a dividend.

Nano X Imaging quarterly revenues are $3M, which are smaller than Compugen quarterly revenues of $17.1M. Nano X Imaging's net income of -$13.6M is lower than Compugen's net income of $1.3M. Notably, Nano X Imaging's price-to-earnings ratio is -- while Compugen's PE ratio is 75.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nano X Imaging is 45.73x versus 3.36x for Compugen. Usually stocks with elevated PS ratios are considered overvalued.

BiomX has a net margin of -449.98% compared to Nano X Imaging's net margin of --. Nano X Imaging's return on equity of -26.97% beat BiomX's return on equity of --.

Nano X Imaging has a consensus price target of $15.00, signalling upside risk potential of 78.36%. On the other hand BiomX has an analysts' consensus of $7.00 which suggests that it could grow by 812.41%. Given that BiomX has higher upside potential than Nano X Imaging, analysts believe BiomX is more attractive than Nano X Imaging.

Nano X Imaging has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BiomX has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.797%.

Nano X Imaging has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BiomX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nano X Imaging pays -- of its earnings as a dividend. BiomX pays out -- of its earnings as a dividend.

Nano X Imaging quarterly revenues are $3M, which are larger than BiomX quarterly revenues of --. Nano X Imaging's net income of -$13.6M is lower than BiomX's net income of $9.6M. Notably, Nano X Imaging's price-to-earnings ratio is -- while BiomX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nano X Imaging is 45.73x versus -- for BiomX. Usually stocks with elevated PS ratios are considered overvalued.

Pluri has a net margin of -449.98% compared to Nano X Imaging's net margin of -1804.3%. Nano X Imaging's return on equity of -26.97% beat Pluri's return on equity of -438.78%.

Nano X Imaging has a consensus price target of $15.00, signalling upside risk potential of 78.36%. On the other hand Pluri has an analysts' consensus of -- which suggests that it could grow by 640.74%. Given that Pluri has higher upside potential than Nano X Imaging, analysts believe Pluri is more attractive than Nano X Imaging.

Nano X Imaging has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pluri has a beta of 1.664, suggesting its more volatile than the S&P 500 by 66.393%.

Nano X Imaging has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pluri offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nano X Imaging pays -- of its earnings as a dividend. Pluri pays out -- of its earnings as a dividend.

Nano X Imaging quarterly revenues are $3M, which are larger than Pluri quarterly revenues of $326K. Nano X Imaging's net income of -$13.6M is lower than Pluri's net income of -$5.9M. Notably, Nano X Imaging's price-to-earnings ratio is -- while Pluri's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nano X Imaging is 45.73x versus 38.38x for Pluri. Usually stocks with elevated PS ratios are considered overvalued.